Verition Fund Management’s Edesa Biotech EDSA Stock Holding History

Verition Fund Management’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,929	Closed	-$100K	–	2609
2021 Q3	$100K	Buy	+1,929	New	+$75.1K	﹤0.01%	1709

Other funds holding EDSA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Verition Fund Management's EDSA Position: Q4 2021 in Review

Verition Fund Management sold out of Edesa Biotech (EDSA) in Q4 2021, closing a stake of 1,929 shares — an estimated $100K sold.

Verition Fund Management first reported a position in EDSA in Q3 2021 and held it in 1 quarter. The position peaked at $100K in Q3 2021. 25 funds tracked by Wall St. Rank hold EDSA as of Q4 2021.

Verition Fund Management reported no remaining Edesa Biotech position as of Q4 2021 after selling out during the quarter.
Verition Fund Management sold 1,929 Edesa Biotech shares in Q4 2021, an estimated $100K.
Verition Fund Management first reported a position in Edesa Biotech in Q3 2021 and held it in 1 quarter.
Verition Fund Management's Edesa Biotech position peaked at $100K in Q3 2021.
25 funds tracked by Wall St. Rank held Edesa Biotech as of Q4 2021.

Based on Verition Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.